Differential signalling in human cannabinoid CB₁ receptors and their splice variants in autaptic hippocampal neurones

Abstract

BACKGROUND AND PURPOSECannabinoids such as D 9 -tetrahydrocannabinol, the major psychoactive component of marijuana and hashish, primarily act via cannabinoid CB1 and CB2 receptors to produce characteristic behavioural effects in humans. Due to the tractability of rodent models for electrophysiological and behavioural studies, most of the studies of cannabinoid receptor action have used rodent cannabinoid receptors. While CB1 receptors are relatively well-conserved among mammals, human CB1 (hCB1) differs from rCB1 and mCB1 receptors at 13 residues, which may result in differential signalling. In addition, two hCB1 splice variants (hCB1a and hCB1b) have been reported, diverging in their amino-termini relative to hCB1 receptors. In this study, we have examined hCB1 signalling in neurones. EXPERIMENTAL APPROACHhCB1, hCB1a hCB1b or rCB1 receptors were expressed in autaptic cultured hippocampal neurones from CB1 -/-mice. Such cells express a complete endogenous cannabinoid signalling system. Electrophysiological techniques were used to assess CB1 receptor-mediated signalling. KEY RESULTSExpressed in autaptic hippocampal neurones cultured from CB1 -/-mice, hCB1, hCB1a and hCB1b signal differentially from one another and from rodent CB1 receptors. Specifically, hCB1 receptors inhibit synaptic transmission less effectively than rCB1 receptors. CONCLUSIONS AND IMPLICATIONSOur results suggest that cannabinoid receptor signalling in humans is quantitatively very different from that in rodents. As the problems of marijuana and hashish abuse occur in humans, our results highlight the importance of studying hCB1 receptors. They also suggest further study of the distribution and function of hCB1 receptor splice variants, given their differential signalling and potential impact on human health. LINKED ARTICLESThis article is part of a themed section on Cannabinoids in Biology and Medicine. To view the other articles in this section visit http://dx.doi.org/10.1111/bph.2012.165.issue-8. To view Part I of Cannabinoids in Biology and Medicine visit http://dx

Cannabinoid Receptor–Interacting Protein 1a Modulates CB1 Receptor Signaling and Regulation

“…To determine whether CRIP 1a over expression would suppress constitutive inhibition of EPSCs by CB 1 Rs, the effects of rimonabant (100 nM) were examined. However, no effect of this inverse agonist was detected regardless of whether CRIP 1a was overexpressed (data not shown), as previously reported for nontransfected hippocampal autaptic cultures (Straiker et al, 2012).…”

Biased Agonism of Three Different Cannabinoid Receptor Agonists in Mouse Brain Cortex

“…For example, when evaluating the cannabinoid effects on brain-stimulation reward, Fattore et al (2003) showed that the potent non-selective CB 1 /CB 2 receptor agonists WIN55,212-2 and CP 55,940, but not Δ 9 -THC, effectively restored heroin-seeking behavior. In addition, it has been suggested that the signaling of CB 1 receptors may differ between humans and rodents (Straiker et al, 2012). …”

Iron overload causes osteoporosis in thalassemia major patients through interaction with transient receptor potential vanilloid type 1 (TRPV1) channels

“…Although these receptor isoforms seem to exhibit similar pharmacology, they may have different functions in cell physiology. 44 Indeed, the majority of our knowledge of the cannabinoid receptors is in relation to their ligands and receptor binding sites, second messengers or signal transduction mechanisms, and postreceptor intracellular protein-protein interactions. Little, however, is known about regulation of CB1 or CB2 gene expression.…”